Big Pharma is rethinking the clinical trials process, establishing tighter links between clinical R&D and discovery. The buzzword is experimental medicine--a catchall for the set of tools and clinical strategies used to determine whether hitting a drug target modulates a disease process in a therapeutically useful way. By so doing, companies hope to reign in clinical costs--the bulk of drug development expenses--by avoiding massive drilling into what prove to be dry drug development holes. To some, experimental medicine is also a process to create a bridge between discovery research and clinical R&D--a large task given that they hold different mindsets.
By Mark L. Ratner
Over the past decade, spurred by the availability of genomics data, chemistry-oriented Big Pharma has acquired the toolkits of molecular...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.
Aneesh Karatt-Vellatt is leading the charge to redefine how ion channels and G protein-coupled receptors (GPCRs) are targeted with antibody therapies, one of the most notoriously challenging classes of drug targets.
In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.
